Cyrus Mozayeni follows ADC 'beacon' to Pheon CEO role; BeiGene loses business chief to Teva
28 Jul 2023
Executive ChangeGene Therapy
Cyrus Mozayeni has been around the biotech business long enough not to be fazed when things don’t go as expected.
Soon after he closed his last startup in April, Vedere Bio II — a gene therapy biotech born out of another that was sold to Novartis — he returned to his network at Atlas Venture, where he is entrepreneur-in-residence, to scout new opportunities. Earlier this month, he started a new job as CEO of Pheon Therapeutics to replace Bertrand Damour at the Atlas-backed company.
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.